MONTPELLIER, France – Contract research company KYomed celebrated its fourth anniversary this year by changing its name and launching a new digital tool.
Now called KYomed INNOV, the company wants to make sure its focus in e-health is on innovation and the human factor.
“When we started, we had an idea of the environment we were in and what we wanted to do, but that has matured over time,” said Sabrina Serpillon, business development manager for KYomed INNOV. “Everything we do now is about involving human beings into innovation.”
KYomed INNOV offers integrated services that help companies accelerate the development and commercialization of innovative products in health care and personal autonomy, Serpillon said. Recent projects have included: evaluating the use and functionalities of a connected pillbox prototype developed by Sanofi; and coordinating a global project to develop and assess a mobile app for preventing, optimizing and personalizing treatment for allergic rhinitis.
The company is currently coordinating the development of a mobile app that will collect data for project POLLAR, which aims to define the link between pollution, pollen and respiratory conditions.
Serpillon said KYomed INNOV’s services can help companies adapt their technology for wider use and expand their markets.
“Many products are developed for one country but can easily be adapted for use in many others,” she said. “People in Europe live differently than those in the U.S.; connected devices have to be adapted to the country where they’ll be used.”
KYomed INNOV recently introduced ePRO (electronic patient reported outcomes), a software suite that includes an application for use by the patient and a web-based platform for use by clinical investigators. Patients fill out a standard or customized scientific electronic questionnaire that relates to the symptoms experienced, as well as the impact of the medical intervention on the patient’s quality of life. Investigators can view the data through a platform, which integrates with other software in their practice.
“Thanks to this tool, our clients will be able to integrate all of these data points into their clinical studies and strengthen their applications with a view to achieving a CE and/or (U.S. Food and Drug Administration) mark,” Serpillon said.